US 12,465,635 · Application 17/545,894 · Granted Nov 11, 2025
US 12,465,635
Methods of treating inflammatory arthritis using secukinumab
Estimated expiration
December 15, 2031
5y 42d remaining
- Could not fetch continuity data for application PCTEP2011069476: Resource not found (404)
Earliest effective filing
Nov 4, 2011
+ 20 years
Nov 4, 2031
PTA +756d
Nov 29, 2033
TD cap (US 10,363,307)
Dec 15, 2031
Final
Dec 15, 2031
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- December 8, 2021
- Earliest effective filing
- November 4, 2011
- Issue date
- November 11, 2025
- PTA
- +756 days
- Base expiry (before PTA)
- November 4, 2031
November 4, 2011 + 20 years = November 4, 2031 + 756 PTA days = November 29, 2033
- Divisional of application 16/439,423, filed Jun 12, 2019
- Divisional of application 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
- Divisional of application 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
- National stage entry of application PCTEP2011069476, filed Nov 4, 2011
- National stage entry of application PCTEP2011069476, filed Nov 4, 2011
- Divisional of application 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
- National stage entry of application PCTEP2011069476, filed Nov 4, 2011
- Divisional of application 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
- Divisional of application 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
- National stage entry of application PCTEP2011069476, filed Nov 4, 2011
- PRO61/410,533 — Provisional — not used for base term
- PRO61/410,533 — Provisional — not used for base term
- PRO61/410,533 — Provisional — not used for base term
- PRO61/410,533 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to December 15, 2031 (earliest expiring referenced patent: US 10,363,307)
US 10,363,307· Application 15/654,854Capping patent
Methods of treating psoriatic arthritis using il-17 antagonists
- Filing date
- Jul 20, 2017
- Earliest effective filing
- Nov 4, 2011
- Issue date
- Jul 30, 2019
- PTA
- +41 days
- Calculated expiration
- Dec 15, 2031
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Nov 4, 2011 + 20y + 41d PTA = Dec 15, 2031
US 12,465,635· Application 17/545,894(from application 17/545,894)
Methods of treating inflammatory arthritis using secukinumab
- Filing date
- Dec 8, 2021
- Earliest effective filing
- Nov 4, 2011
- Issue date
- Nov 11, 2025
- PTA
- +756 days
- Calculated expiration
- Nov 29, 2033
Divisional of 16/439,423, filed Jun 12, 2019
Divisional of 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Divisional of 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Nov 4, 2011 + 20y + 756d PTA = Nov 29, 2033
US 11,534,491· Application 16/824,613
Methods of treating ankylosing spondylitis using il-17 antagonists
- Filing date
- Mar 19, 2020
- Earliest effective filing
- Nov 4, 2011
- Issue date
- Dec 27, 2022
- PTA
- +119 days
- Calculated expiration
- Mar 2, 2032
Divisional of 16/439,423, filed Jun 12, 2019
Divisional of 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Divisional of 15/654,854, filed Jul 20, 2017, issued as US 10,363,307
Divisional of 13/877,585, filed Apr 3, 2013, issued as US 9,744,234
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Nov 4, 2011 + 20y + 119d PTA = Mar 2, 2032
US 9,744,234· Application 13/877,585
Methods of treating ankylosing spondylitis using il-17 antagonists
- Filing date
- Apr 3, 2013
- Earliest effective filing
- Nov 4, 2011
- Issue date
- Aug 29, 2017
- PTA
- +548 days
- Calculated expiration
- May 5, 2033
National stage entry of PCTEP2011069476, filed Nov 4, 2011
Nov 4, 2011 + 20y + 548d PTA = May 5, 2033
Notes (1)
- [TD_DOCS_TRUNCATED] Found 4 filed TD documents; parsing first 3 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/545,894 · US 12,465,635
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,465,635: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12465635Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.